TT:NYSE

Trane Technologies plc

Data as of 2026-03-10 - not real-time

$427.52

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Trane Technologies (TT) is trading at $427.52, which sits just above its 50‑day (456.37) and 200‑day (422.59) SMAs but below the 20‑day SMA, indicating a short‑term pullback within a longer‑term uptrend. The 14‑day RSI of 41.9 and a bearish MACD histogram (‑6.59) reinforce the near‑term downside pressure, while volume is increasing, suggesting that the recent sell‑off is supported by market participation. Volatility remains elevated at 36.6% over the past 30 days, yet the beta of 0.89 points to lower systematic risk than the broader market. Fundamentally, TT delivers strong profitability with a 13.7% profit margin, 36.0% ROE, and 5.6% revenue growth, while maintaining a healthy operating cash flow of $3.19B. The forward P/E of 25.4 is well below the current trailing P/E of 32.1 and the industry average of 29.5, indicating earnings acceleration. Dividend sustainability looks solid, highlighted by a recent 12% increase to $1.05 per quarter and a modest payout ratio of 28.6%. Analyst sentiment is bullish, with a consensus “Buy” rating, a median target of $470 and an implied upside of about 12% from today’s price. Institutional ownership exceeds 50%, and recent coverage from Oppenheimer raised the price objective to $468, reinforcing confidence in the stock’s medium‑term trajectory.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 6/10

Key Factors

  • Bearish MACD and RSI near neutral suggest limited upside
  • Increasing volume confirms short‑term selling pressure
  • Dividend increase provides downside cushion

Medium Term

1–3 years
buy
Conviction: 8/10

Key Factors

  • Forward P/E compression and earnings growth
  • Analyst price targets imply ~12% upside
  • Strong cash flow and high ROE support valuation

Long Term

> 3 years
buy
Conviction: 9/10

Key Factors

  • Climate‑focused product portfolio drives secular demand
  • Sustained dividend growth and low beta reduce risk
  • Robust balance sheet with manageable leverage

Key Metrics & Analysis

Financial Health

Revenue Growth5.60%
Profit Margin13.69%
P/E Ratio32.1
ROE36.96%
ROA11.64%
Debt/Equity63.25
P/B Ratio11.0
Op. Cash Flow$3.2B
Free Cash Flow$1.9B
Industry P/E29.5

Technical Analysis

TrendNeutral
RSI41.9
Support$413.98
Resistance$479.37
MA 20$456.37
MA 50$422.26
MA 200$422.59
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$137.05
Target Price$479.73
Upside/Downside12.21%
GradeFair
TypeBlend
Dividend Yield0.99%

Risk Assessment

Beta0.89
Volatility36.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.